Teva completes acquisition of Allergan generics business
Teva’s acquisition of Allergan’s generic business (Actavis Generics) has been completed, the company revealed yesterday.
The acquisition is intended to improve research and development capabilities, product portfolios and geographical footprints, Teva said in a statement.
Erez Vigodman, CEO of Teva said: “Through our acquisition of Actavis Generics, we are creating a new Teva with a strong foundation.”
Actavis began using the name Allergan in June 2015 after acquiring the company in March of that year.
Teva now has approximately 338 product registrations pending Food and Drug Administration approval, along with 115 pending Abbreviated New Drug Applications in the US.
In total, the Isreal-based company is planning around 1,500 generic launches worldwide in 2017.
Last week, LSIPR reported that the Federal Trade Commission had accepted the $40.5 billion buyout after Teva agreed to sell nearly 80 products to address competition concerns.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk